Monday, 22 April 2024

Cytiva supports Clover Biopharma to scale up output of COVID-19 vaccine candidate

17 November 2020 | News

Clover aims to double its commercial manufacturing capacity in preparation for global Phase 2/3 trials

Image source: PR Newswire

Image source: PR Newswire

US-based Cytiva, a global life sciences leader, is supporting Shanghai-based Clover Biopharmaceuticals, a global clinical-stage biotechnology company, to help accelerate the development and manufacturing of a protein-based S-Trimer subunit vaccine candidate. With promising preliminary safety and immunogenicity results from the Phase 1 clinical study, Clover aims to quickly expand its current 2 x 2000L capacity of the Cytiva FlexFactory, which went into service in January 2020.

Cytiva will help Clover add two more 2000L bioreactors for a total of 4 x 2000L manufacturing capacity through the Cytiva FlexFactory, which will provide a total solution including process equipment, services, and consumables to ensure safety, efficiency, scaled-up capacity for vaccine development.

Clover's COVID-19 S-Trimer vaccine was developed by combining the trimeric SARS-CoV-2 spike (S)-protein with the company's proprietary Trimer-Tag© technology. As the first company in the world to produce a COVID-19 vaccine candidate that is successfully recognized by antibodies produced by previously-infected patients, Clover demonstrates that S-Trimer has preserved the native structure of the viral spike (S) protein and thus may elicit a protective immune response as a vaccine.

Clover's Phase 1 clinical study has completed enrollment of 150 adult and elderly participants. Based on positive preliminary results, an additional 280 participants will be enrolled in a Phase 1 dose-expansion study at a selected S-Trimer dose-level. The company intends to initiate a global Phase 2/3 vaccine efficacy study before the end of 2020. 

The clinical trials and Clover's COVID-19 vaccine program are supported by funding and collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI). The agreement between CEPI and Clover anticipates that the vaccine – if proven to be safe and effective – will be made available for procurement and allocation through the COVAX Facility to those who need it most around the world.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account